Provide feedbackProvide feedback

Home :: General Surgery

Lilly licenses NK-1R antagonist to Vanda Pharmaceuticals

Monday, April 16 2012 | Comments
Evidence Grade 0 What's This?

Eli Lilly and Co. licensed the worldwide rights to LY686017, an investigational small molecule neurokinin 1 receptor (NK-1R) antagonist, to Vanda Pharmaceuticals Inc. The agreement grants Vanda exclusive rights to the drug, which will now be known as VLY-686, in all human indications. The terms of the agreement state that Vanda will pay an initial license fee of $1 million and will be responsible for all development costs. Lilly is eligible to receive development and commercialization...

Eli Lilly and Co. licensed the worldwide rights to LY686017, an investigational small molecule neurokinin 1 receptor (NK-1R) antagonist, to Vanda Pharmaceuticals Inc.

The agreement grants Vanda exclusive rights to the drug, which will now be known as VLY-686, in all human indications.

The terms of the agreement state that Vanda will pay an initial license fee of $1 million and will be responsible for all development costs. Lilly is eligible to receive development and commercialization milestone payments, as well as tiered royalties on net sales. The potential milestone payments include $4 million for milestones achieved prior to approval of a New Drug Application by the Food and Drug Administration and as much as $95 million in future regulatory and sales milestone payments.

Vanda noted that NK-1R antagonists have been evaluated in several indications, including chemotherapy-induced nausea and vomiting (CINV), postoperative nausea and vomiting (PONV), alcohol dependence, anxiety, depression and pruritus.

The firm added that VLY-686 has demonstrated proof of concept in alcohol dependence. In a study published by the National Institutes of Health, the drug reduced alcohol cravings and voluntary alcohol consumption among patients with alcohol dependence.

According to Vanda, the only NK-1R antagonist that is currently marketed in the United States is Merck & Co. Inc.'s Emend (aprepitant), which is approved for the treatment of CINV and the prevention of PONV.

Latest News

AcelRx launches second late-stage study of ARX-01 for treatment of acute postoperative pain Verusmed

Thursday, April 12 2012 | Comments
Evidence Grade 0 What's This?

AcelRx Pharmaceuticals Inc. started a Phase III trial to evaluate ARX-01, the company's sufentanil NanoTab patient-controlled analgesia (PCA) system, for the treatment of acute postoperative pain.

AcelRx described ARX-01 as a preprogrammed, noninvasive, hand-held system that allows patients to self-dose with sublingual sufentanil NanoTabs to manage pain following...



Researchers find overall inverse relationship between hospital volume, preventable adverse events for three major surgical procedures Verusmed

Wednesday, April 11 2012 | Comments
Evidence Grade 0 What's This?

Using patient safety indicators (PSIs) developed by the Agency for Healthcare Research and Quality to identify hospital-acquired adverse events, researchers at Stanford University showed that hospitals that perform a high volume of three different types of surgical procedures have significantly lower risk-adjusted rates of associated preventable adverse events as compared with hospitals that perform a lower volume of...



J&J unit acquires certain IP associated with Angiotech's wound closure products; companies establish related supply agreement Verusmed

Thursday, April 05 2012 | Comments
Evidence Grade 0 What's This?

Angiotech Pharmaceuticals Inc. sold certain intellectual property (IP) associated with its Quill wound closure products to Ethicon Inc., a unit of Johnson & Johnson Inc., and its affiliates.

In exchange for the IP, Ethicon will make an initial payment of approximately $20 million to Angiotech. In addition, Angiotech could earn as much as approximately $42 million...



Durect regains U.S., Canadian rights to pain drug candidate from Hospira Verusmed

Thursday, March 29 2012 | Comments
Evidence Grade 0 What's This?

Durect Corp. said Hospira Inc. would be returning the development and commercialization rights to Posidur, an investigational long-acting formulation of the anesthetic bupivacaine, in the United States and Canada. 

James Brown, Durect's chief executive officer, said the company is disappointed that Hospira will no longer be its...





General Surgery Conference Coverage
  1. No articles have been read
  1. No articles have been emailed
Videos